Current Issue

Most cases of prediabetes in older adults did not progress to diabetes, study finds

A cohort study of older adults found a high prevalence of prediabetes, but during more than six years of follow-up, death or regression to normoglycemia was more common than progression to diabetes.

Studies find link between metformin and reduced COVID-19 mortality, mixed results for DPP-4 inhibitors

Prior metformin use was associated with a threefold decrease in mortality from COVID-19 in one study of patients with type 2 diabetes, while three other studies found mixed results on whether dipeptidyl peptidase-4 (DPP-4) inhibitors affect COVID-19 outcomes.

Choice of SGLT-2 inhibitors, GLP-1 receptor agonists should be based on individual risk

A meta-analysis comparing sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists found differing effects, including that the SGLT-2 inhibitors affected heart failure outcomes while GLP-1 receptor agonists reduced stroke risk.

MKSAP quiz: Ketoacidosis at diabetes diagnosis

This month's quiz asks readers to evaluate a 50-year-old man who was hospitalized for diabetic ketoacidosis 3 months ago but had no previous history of diabetes mellitus.

Spotlight on pregnancy in women with diabetes

Recent studies looked at aspects of pregnancy in women with pre-existing type 1 or 2 diabetes, including rates of adverse outcomes, useful biomarkers, and typical dietary patterns.

Continuous glucose monitoring gains traction in hospitals

An article in the February ACP Hospitalist covers how some hospitals have rapidly transitioned inpatient continuous glucose monitoring from research into practice in response to COVID-19.

Studies analyze amputation rates with sodium–glucose cotransporter-2 inhibitors

An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.